Aditx Therapeutics(ADTX)
搜索文档
Appili Therapeutics Announces Results of Special Meeting of Shareholders
GlobeNewswire News Room· 2024-11-07 06:55
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, today announced the results from its special meeting of shareholders held earlier today (the “Meeting”). Shareholders of the Company (the “Shareholders”), overwhelming ...
Appili Therapeutics Announces Third Amendment to Arrangement Agreement and Provides Updated on Transaction with Aditxt
GlobeNewswire News Room· 2024-08-21 19:15
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Aug. 21, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a third amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and toge ...
Aditx Therapeutics(ADTX) - 2024 Q2 - Quarterly Report
2024-08-20 04:16
公司概况 - 公司成立于2017年9月,总部位于加州山景城[141] - 公司成立的初衷是通过整合利益相关方来推动创新,将最有前景的创新转化为能满足最迫切需求的产品和服务[141] - 公司最初专注于免疫调节技术ADI/Adimune,后来扩展了创新组合[141] 子公司业务 - 子公司Adimune专注于免疫调节治疗项目,其主要产品候选药物ADI-100正在开展针对中枢神经系统自身免疫疾病的临床试验[142][143] - 子公司Pearsanta致力于将个性化医疗推向新高度,正在开发一个集样本采集、样本处理和报告于一体的数字化医疗平台[146][147][148] - 公司最近成立了子公司Adivir,专注于开发创新抗病毒产品[152] 知识产权 - 公司已获得斯坦福大学和罗马林达大学的相关技术专利许可,用于开发AditxtScore和ADI技术[145][151] 财务状况 - 公司目前资金不足,存在持续经营的重大不确定性[154] - 公司自成立以来经营历史较短,财务信息有限,未来盈利前景存在不确定性[155] - 2024年6月30日季度营收为44,276美元,同比下降80%,毛利为21,142美元[156] - 2024年6月30日半年营收为123,956美元,同比下降72%,毛利为35,023美元[157] - 2024年6月30日半年期间净亏损17,511,627美元,主要由于研发费用大幅增加和支付1,000,000美元并购费用[158] - 公司存在持续亏损的风险,2024年6月30日累计亏损150,024,555美元,流动资金为负1,905.9万美元[158] - 公司通过多次私募融资筹集资金用于偿还债务和维持运营[158] - 公司存在持续经营能力的不确定性[159] 内部控制缺陷 - 公司存在内部控制缺陷,正在采取补救措施[166] - 公司未维持充分的会计和财务报告政策及程序文档[166] - 公司未保留足够的技术和复杂会计问题识别及记录人员[166] - 公司未维持充分的应付账款识别和截止程序[166] - 上述重大缺陷导致财务报表出现重大错报,已得到更正,但未影响之前发布的财务结果[166] - 公司正在补救这些重大缺陷[166] - 本季度内部控制未发生重大变化[167] 诉讼风险 - 公司可能不时卷入一些日常业务中的诉讼和法律程序,但这些诉讼存在固有不确定性,可能会对业务造成不利影响[168]
Biotech News: Why Is Aditxt (ADTX) Stock Up 49% Today?
Investor Place· 2024-08-08 00:43
Aditxt (NASDAQ:ADTX) stock is rising higher on Wednesday after the company notified investors of an update on a clinical trial conducted by its subsidiary Pearsanta.According to a press release from Aditxt, Pearsanta has submitted a Clinical Trial Translational Endpoints Research Award proposal to the Congressionally Directed Medical Research Programs (CDMRP) of the Department of Defense.Aditxt notes that this proposal seeks to validate a novel assay based on Pearsanta’s Mitomic Technology. The goal would b ...
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
GlobeNewswire News Room· 2024-07-25 21:00
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women’s health innovator Evofem Biosciences, Inc. (“Evofem” or “the Company”) (OTCQB: EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webcast:(live and archive)https://bit.ly/3LySuJNor archive: https://evofem.investorroom.com/events Durin ...
Evofem Biosciences to Present at the OTCQB Venture Virtual Investor Conference on August 1st
Newsfilter· 2024-07-25 21:00
SAN DIEGO, July 25, 2024 (GLOBE NEWSWIRE) -- Women's health innovator Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCQB:EVFM) today announced that Saundra Pelletier, Chief Executive Officer and Amy Raskopf, Chief Business Development Officer, will present and host one-on-one meetings at the OTCQB Venture Virtual Investor Conference as follows: Date:Thursday, August 1, 2024Time:10:30am ETAccess Webcast:(live and archive)https://bit.ly/3LySuJNor archive: https://evofem.investorroom.com/events During ...
Evofem Signs Phexxi® License Agreement for Middle East with Pharma 1
Prnewswire· 2024-07-23 20:47
文章核心观点 - 女性健康创新公司Evofem Biosciences与阿联酋医疗公司Pharma 1签署了Phexxi在中东地区的许可和供应协议 [2][3][4][5] - Pharma 1将负责在中东地区包括阿联酋、科威特、沙特阿拉伯、卡塔尔等国家获得Phexxi的监管批准,并负责分销、销售、营销等商业运营 [3][4] - 阿联酋避孕药市场预计到2030年将达到1.851亿美元 [2] - Phexxi是FDA批准的首个无激素、按需使用的避孕凝胶,可维持阴道正常微生物环境,对精子和某些病原体不利 [7] - Evofem公司还收购了FDA批准的口服抗生素SOLOSEC,用于治疗滴虫病和细菌性阴道炎 [9] - Evofem公司正与Aditxt公司进行并购,预计于2024年9月30日完成 [10] 公司概况 - Evofem Biosciences是一家专注于女性性健康和生殖健康的创新型公司,主要产品包括Phexxi和SOLOSEC [8][9] - Pharma 1是一家阿联酋公司,致力于为海湾合作委员会(GCC)地区提供基于科学研究和调查的实用性医疗解决方案 [11] 行业概况 - 阿联酋避孕药市场预计到2030年将达到1.851亿美元,反映了对无激素、按需避孕产品的需求增长 [2][4]
Appili Therapeutics Announces Second Amendment to Arrangement Agreement
GlobeNewswire News Room· 2024-07-19 05:07
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, July 18, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI; OTCPink: APLIF) (the “Company” or “Appili”), a biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures, announces that it has entered into a second amending agreement (the “Amending Agreement”) among the Company, Aditxt, Inc. (“Aditxt”) and Adivir, Inc. (“Adivir” and tog ...
Why Is Aditxt (ADTX) Stock Up 72% Today!
Investor Place· 2024-07-17 20:23
Aditxt (NASDAQ:ADTX) stock is up on Wednesday after the biotech company announced an amended and restated merger agreement with Evofem Biosciences (OTCMKTS:EVFM).Aditxt notes that the merger agreement was amended and restated as Evofem Biosciences has some critical needs ahead of it. That includes interim financing and substituting cash for shares of ADTX stock in the merger.Aditxt also notes that it has acquired SOLOSEC from Lupin Limited. This grants Lupin Limited a potential of $84 million based on futur ...
Lupin Divests U.S. Commercial Women's Health Specialty Business to Evofem, including SOLOSEC
Prnewswire· 2024-07-15 19:20
文章核心观点 - 全球制药巨头Lupin有限公司(Lupin)宣布将其美国商业妇女健康专业业务,包括SOLOSEC®(secnidazole)2g口服颗粒剂,出售给美国生物制药公司Evofem Biosciences公司[1][3][4] - 根据交易条款,Lupin可能获得高达8400万美元的潜在总对价,取决于未来的或有里程碑[2] - Evofem表示此次收购与其提高妇女性和生殖健康创新和差异化选择的使命一致,SOLOSEC是一种具有巨大增长潜力的单剂量口服抗生素,可治疗两种广泛存在的性健康感染[4] 公司概况 - Lupin是一家总部位于印度孟买的创新型跨国制药公司,在全球100多个市场开发和销售各种品牌和仿制药、生物技术产品和原料药[5] - Lupin在心血管、抗糖尿病和呼吸系统领域占据领导地位,在抗感染、胃肠道、中枢神经系统和妇女健康领域也有重要地位,是美国第三大制药公司[6] - Lupin拥有15个制造基地、7个研发中心,全球拥有2万多名员工,连续被评为"最佳工作场所"[7] 产品概况 - SOLOSEC®是FDA批准的首个单剂量口服处方药,可治疗细菌性阴道炎和滴虫病,这两种常见的性健康感染[11] - SOLOSEC®设计简单易用,一次口服剂量即可完成全程治疗[11]